. Although the locus of the gene involved in MCKD1 was subsequently refined [12, 13] , it remained unknown for a long time [14] , until Kirby et al. [3] showed that a mutation in MUC1 was responsible, in 2013. MCKD1 has since been re-classified as ADTKD-MUC1 [15] . MUC1 is a transmembrane protein that is arranged on the apical surface of most epithelial cells. In the kidney, MUC1 is expressed at the thick ascending limb, distal tubule and collecting duct [16] . MUC1 has an extracellular domain containing a variable number of tandem repeats (VNTRs) and a sea urchin sperm protein, enterokinase and agrin module. The extracellular domain is cleaved at the cleavage site in the sea urchin sperm protein, enterokinase and agrin module and binds to the transmembrane domain non-covalently ( Figure 1A and B). Because the VNTR region contains 20-125 copies of a GC-rich 60 base pair sequence coding 20 amino acids, including five serine or threonine residues that serve as sites for O-linked glycosylation by N-acetylgalactosamine, MUC1 is a highly O-glycosylated protein ( Figure 1B ) [3, [17] [18] [19] . Kirby et al. revealed a single cytosine insertion in a single copy of the VNTR sequence by cloning, capillary sequencing and de novo assembly ( Figure 1C ). It required an immense amount of time and effort to detect this mutation because massively parallel sequencing cannot read the VNTR of MUC1 because of its tertiary structure [3] . This frameshift mutation creates a new peptide containing many copies of a novel 20 amino acid repeat sequence of 'SPRCHLGPGHQAGPGLHRPP' ( Figure 1D ). The mutant MUC1 protein was identified in the cytoplasm of patient renal epithelial cells, but not on cell membranes, with a specific antibody against the mutant repeat sequence, suggesting trafficking abnormalities [3] . To date, this single cytosine insertion in the VNTR sequence is the only mutation that has been reported to be responsible for ADTKD-MUC1.
In this study, we identified a new ADTKD-MUC1 family with a previously uncharacterized frameshift mutation. Their entirely novel mutation site of MUC1 was unexpectedly discovered by next-generation sequencing-driven exome analyses. This mutation was located before the VNTR sequence, which enabled us to construct expression vectors for the mutant MUC1 protein. We describe the characteristic features of the mutant MUC1 protein, which may facilitate our understanding of the mechanism of ADTKD-MUC1.
M A T E R I A L S A N D M E T H O D S

Clinical evaluation
Informed consent was obtained from all 15 family members in accordance with the guidelines of the ethics committee of Osaka University (protocol number: 618). The medical records of the family were obtained by interviewing the affected family members. Clinical data of patient IV-3, including laboratory data, imaging data and kidney biopsy, were also obtained with informed consent.
DNA extraction, whole-exome sequencing and variant analysis pipeline Genomic DNA of family members was isolated from peripheral blood via NucleoSpin (MACHEREY-NAGEL, Düren, Germany). Trio-based whole-exome sequencing was applied to patient IV-3 and her parents (Figure 2A ). After quality checks by agarose electrophoresis, 3 lg genomic DNA was converted to 100 bp fragments by a focused ultrasonicator (E220; Covaris, Woburn, MA, USA). Using these short genomic DNA fragments, a DNA library was constructed according to the manufacturer's instructions (SureSelectXT Target Enrichment System for Illumina Multiplexed Sequencing Version 1.8; Agilent Technologies, Santa Clara, CA, USA). Exomes were captured by streptavidin-conjugated magnetic beads (SureSelectXT Reagent kit; Agilent) after hybridization of the DNA library with the exome capture library (SureSelectXT Human All Exon v5; Agilent). The sequence libraries were prepared using the captured exomes as templates. Quality and size checks of the constructed sequence library were performed using a 2100 Bioanalyzer (Agilent). The libraries were sequenced using a HiSeq 2500 (Illumina, Santa Clara, CA, USA) using 101 bp paired-end reads. Exome sequencing data processing and base calls were performed using HiSeq Control Software v2.0.12, Real Time Analysis v1.17.21.3 and CASAVA v1.8.2. For every family member, sequence reads were converted using Perl scripts from the Illumina fastq format to fastq files that conform to the Sanger specification for base quality encoding. Burroughs-Wheeler Alignment version 0.7.10 was used to align the sequencing reads to the human reference sequence (hg19) with default parameters used for fragment reads [20] . Alignments were converted from the sequence alignment map (SAM) format to sorted and indexed BAM files by SamTools. Picard tools was used to remove invalid alignments and duplicate reads from the BAM files. Regions surrounding potential insertion/deletions (indels) were realigned with genome alignment tool kit (GATK) 2.5-2 IndelRealigner [21] .
The variant analysis pipeline consists of two pipelines: variant calling and variant selection pipelines. Genotypes were called with GATK 2.5-2 UnifiedGenotyper. We analyzed the union of single nucleotide variants and indel variant calls from GATK by the annotate variation (ANNOVAR) program to identify exonic or splicing variants with their allele frequency and functional annotation [22] . The locations and genotypes of variants for each individual were analyzed to locate the subset of variants on the autosomal chromosome. All variant calls on X and Y chromosomes were removed considering the mode of inheritance in this family. Variants with either quality scores below 50, a read depth of less than 5 or a QUAL score normalized by allele depth below 1.5 were filtered out. Output files from GATK were in variant call format (VCF) format.
All variants were annotated with the ANNOVAR program with respect to their frequency in the 1000 Genomes Project, the national heart, lung, and blood institute (NHLBI) Exome Sequencing Project and the Exome Aggregation Consortium. Effects on coding features were analyzed using Perl scripts against the following three databases: refGene tracks from the National Center for Biotechnology Information Reference Sequence Database, knownGene tracks from University of California Santa Cruz Known Genes and ensGene tracks from Ensemble Genes [22, 23] . We focused on heterozygous mutations after assuming autosomal dominant inheritance in the family. Candidate heterozygous variants were selected according to the following criteria: (i) either an exonic or splice site in at least one database; (ii) either non-synonymous, splice site, indel, stop gain/loss or unknown variants in at least one database; (iii) PASS in GATK annotation; and (iv) a minor allele frequency of <0.1% in the total population in the 1000 Genomes Project or ESP6500, or in the East Asian population of the Exome Aggregation Consortium.
Additional subjects and detailed methods are described in Supplementary data Note S2.
R E S U L T S
Case study
The pedigree of this family is shown in Figure 2A . Patients with renal disease are marked in blue. All of them except for IV-3 were in end-stage renal failure, of whom three (III-3, -7 and -10) were renal transplant recipients and one (III-9) was receiving dialysis. No diagnosis was made for any of these patients because they initially presented with end-stage renal failure. The family came to our attention through proband IV-3. She visited our hospital at 23 years of age, suffering from obvious chronic kidney disease (CKD). Her renal function had been gradually declining for 10 years, and at 23 years of age, her renal function
had decreased dramatically, resulting in ESRD at 24 years of age ( Figure 2B ). At 23 years of age, her blood exam showed only renal dysfunction: 20.8 mg/dL blood urea nitrogen, 1.44 mg/dL serum creatinine and 1.28 mg/L cystatin C with no abnormalities in electrolyte status or uric acid. There were no urine abnormalities, with markers of tubular damage (such as urinary Nacetyl-b-D-glucosaminidase and urinary b2 microglobulin) also within the normal range. Her renal MRI scan showed normal sized kidneys with no medullary cysts ( Figure 2C ). Clinical summaries of the patient family members are described in Supplementary data Note S1 and Table S1 . Generally, this family experienced renal failure early in their lives (ESRD before their early 40s).
Light microscopic findings of the renal biopsy of IV-3 showed markedly fibrotic interstitium with infiltration of lymphocytes, stratified epithelial cells and irregularly thickened and multi-layered tubule basement membranes ( Figure 2D and Supplementary data Figure S1A and B). The glomeruli had no remarkable changes, only a multi-stratified and thickened Bowman's capsule (Supplementary data Figure S1C ). Electron microscopy showed that the basement membranes of the tubules were irregularly flexed, thickened, thinned, multi-stratified and partially hyalinized ( Figure 2E and Supplementary data Figure S1D and E). Based on the above findings, this renal disease was diagnosed as ADTKD.
Next-generation sequencing-driven trio exome analyses
To detect the gene causing ADTKD in this family, we analyzed the genomic DNA sequences of III-3 and -4, and IV-3, by next-generation sequencing. Analysis pipelines described in the 'Materials and methods' section identified 124 possible pathogenic candidate variants (Supplementary data Table S2 ). Among these candidates, there were three genes that are known causal genes of renal disease: MUC1, UMOD and SDCCAG8.
We sequenced the detected mutations of MUC1 (chromosome 1:155161911_155161912delAG), UMOD (chromosome 16: 20357449G > A) and SDCCAG8 (chromosome 1:2435421 37G > A) in the other available nine family members by Sanger sequencing. Whereas the UMOD mutation was found in an over 60-year-old healthy family member and the SDCCAG8 mutation was not found in some diseased family members, the MUC1 mutation was found in all patient members and not in any healthy members of this family. Therefore, we identified MUC1 (chromosome 1:155161911_155161912delAG) as a causal mutation, which was a 2 bp (AG) deletion located just before the VNTR, causing a frameshift ( Figure 1C and Supplementary data Figure  S2 ). Interestingly, the consequently produced mutant MUC1 protein is a truncated protein with the amino acid repeat sequence of 'SPRCHLGPGHQAGPGLHRPP', which is almost the same as a previously reported mutant protein ( Figures 1D and E , and 3B and C). The amino acid sequence identity was 87% positive. In TM alignment analysis, both proteins had very similar predicted 3D structures [template modeling (TM) score 0.94595 that was normalized by the previously reported mutant protein length] [24] [25] [26] . Both mutant MUC1 proteins were almost equally different from the wild-type (wt) MUC1 protein (TM score 0.75955 with the previously reported mutant MUC1 and TM score 0.74174 with this mutant MUC1) ( Figure 3A-C) . Based on these 
| | | | | | | | | | | | | | | | | | | | |
results, we concluded that this family's disorder is ADTKD-MUC1. Therefore, the amino acid repeat sequence may be important for the pathophysiology of ADTKD-MUC1.
Localization of recombinant and native mutant MUC1 proteins
The previously reported MUC1 mutation sites in ADTKD-MUC1 patients were localized to the VNTR, which made it very difficult to use conventional gene targeting techniques. However, our newly identified MUC1 mutation site is located before the VNTR. Taking advantage of our mutation sequence, we prepared a mutant MUC1 expression vector (VNTR, n ¼ 22). Recombinant plasmids were transfected into mouse inner medullary collecting duct (mIMCD3) cells and protein localization was examined by immunofluorescence confocal microscopy. Via immunofluorescent staining, wt MUC1 protein was observed on the cell membrane ( Figure 3D ). In contrast, the mutant MUC1 protein remained in the cytoplasm, suggesting inhibition of trafficking to the cell membrane ( Figure 3E ). We also immunostained the mutant MUC1 protein in patient IV-3 kidney tissue. Consistent with the results of the recombinant mutant MUC1 protein, native mutant MUC1 protein was identified intracellularly in distal tubules with a granular pattern, which occasionally colocalized with wt MUC1 protein on the apical membranes. The intracellular pattern was also observed for wt MUC1 protein in contrast to the control kidney tissue of III-4 ( Figure  3F ), in which wt MUC1 protein was stained only on the apical membrane ( Figure 3G ).
Biochemical characteristics of the recombinant mutant MUC1 protein
The mutant MUC1 protein was predicted to lose its role as a scaffold for O-linked glycosylation, because it has only one serine residue in its 20 amino acid VNTR sequence. We confirmed the glycosylation state of the mutant MUC1 protein in vitro. Wt and mutant MUC1 proteins were purified via immunoprecipitation from whole-cell lysates of transfected HEK293T cells and were deglycosylated. These samples were assayed via western blotting. The band of wt MUC1 above 250 kDa disappeared upon the addition of O-glycosidase, indicating that the band was glycosylated wt MUC1 protein ( Figure 4B ). The size (120 kDa) of the precursor protein of wt MUC1 was not changed by O-glycosidase treatment. The size of mutant MUC1 protein was unchanged by addition of O-glycosidase ( Figure  4A ). We also assayed whole-cell lysates of transfected HEK293T cells via western blotting and found that the bands of mutant MUC1 protein were not only at the expected size of 60 kDa, but also at the larger size of 250 kDa ( Figure 4C ). After treatment with 8 M urea as a denaturing agent, the larger band disappeared and only the band at 60 kDa could be observed. This result suggests that the mutant MUC1 protein self-aggregated in the cells. In contrast, the band size of wt precursor MUC1 protein was unaffected by the addition of urea ( Figure 4D) .
Identification of the mutant MUC1 protein in urinary exosomes
We could not extract native mutant MUC1 protein from the small kidney biopsy sample. Therefore, we focused on urine exosomes because wt MUC1 protein has already been identified in urinary exosomes [27] . We speculated that the mutant MUC1 protein might also be detected in urinary exosomes. In IV-3 exosomes, wt MUC1 protein was markedly reduced compared with healthy controls ( Figure 4F ). In contrast, using the anti-mutant MUC1 protein antibody, there was a specific band in IV-3 that was not seen in healthy controls ( Figure 4E ). These data suggest that mutant MUC1 protein can also be detected in urinary exosomes of ADTKD-MUC1 patients.
D I S C U S S I O N
In contrast to the previously reported MUC1 mutation in ADTKD-MUC1, we identified a family with an entirely novel MUC1 mutation before the VNTR, which could be detected by next-generation sequencing-driven whole-exome analysis. This novel mutation was predicted to produce a mutant MUC1 protein with the same repeat sequence as reported previously. Indeed, we identified a mutant MUC1 protein in the kidney of ADTKD-MUC1 patients using the antibody against the repeat sequence in the same pattern as the previously reported case. This result indicates that the repeat sequence is essential for the pathogenesis of ADTKD-MUC1. We also identified a wellknown gene, UMOD, as the candidate causal gene responsible for ADTKD. However, its mutation was also found in an elder healthy family member. Therefore, we excluded mutations in UMOD as being causative.
Conversely, wt MUC1 protein was also observed in the cytoplasm, although Kirby et al. reported that wt MUC1 protein was only stained on the apical membrane. In the hypoxic state, MUC1 is known to be induced and expressed in the cytoplasm [28, 29] . Because renal biopsy of IV-3 was performed at the endstage, we suspect that the hypoxic state might have changed the expression pattern of wt MUC1 protein. Because there may be other ADTKD-MUC1 families with a mutation outside of the VNTR, massive parallel sequencing may be worth performing in suspected ADTKD-MUC1 families. As a non-invasive method to diagnose ADTKD-MUC1, we also focused on urinary exosomes, which are secreted into the urine from all parts of the nephron, because urinary exosomal proteins are expected to act as biomarkers of kidney disease [30, 31] . Wt MUC1 protein has already been successfully identified in urinary exosomes [32, 33] . Therefore, we analyzed the mutant MUC1 protein in urinary exosomes of ADTKD-MUC1 patient by western blotting. A specific band of the mutant MUC1 protein was seen in patient exosomes, but not in healthy controls. These data suggest that the mutated MUC1 protein is present in urinary exosomes of ADTKD-MUC1 patients. Furthermore, wt MUC1 protein was significantly reduced compared with healthy controls. These data indicate that urinary exosomes may be used for nongenetic testing of ADTKD-MUC1.
C O N C L U S I O N
Here, we have described the significance of the mutated MUC1 protein in ADTKD-MUC1 pathogenesis. Believing that characterization of the mutated MUC1 protein may facilitate our understanding of the disease mechanism, we constructed an expression vector for the mutant MUC1 protein with the same mutation found in the ADTKD-MUC1 patients of this family with relative ease because it was outside of the VNTR. In mIMCD3 cells transfected with the mutant MUC1 expression vector, mutant MUC1 protein was localized in the cytoplasm, whereas wt MUC1 protein was predominantly on the cell membrane in wt MUC1 expression vector-transfected mIMCD3 cells. Additionally, the mutant MUC1 protein was predicted to lose the glycosylation site in its VNTR because of the reduction of serine and threonine residues [3] . Furthermore, we revealed the possibility of selfaggregation of the mutant MUC1 protein in transfected HEK293T cells by western blot analysis. We confirmed colocalization of the endoplasmic reticulum marker GRP78 with the ADTKD-MUC1 kidney (Supplementary data Figure S3 ). Based on these biochemical data, it is possible that the mutant protein may induce the unfolded protein response in cells. Thus, the developed mutant MUC1 protein expression system could be a unique tool to explore the disease mechanisms of ADTKD-MUC1 in the future.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxfordjour nals.org.
A C K N O W L E D G E M E N T S
We thank Dr Rebecca P. Hughey 
C O N F L I C T O F I N T E R E S T S T A T E M E N T
None declared.
R E F E R E N C E S
